Brief: Egetis Secures Conditional Acceptance For Emcitate® As Brand Name In The U.S

Egetis Therapeutics AB (publ)

26/01/2022 07:09

Jan 26 (Reuters) - Egetis Therapeutics AB (publ)  EGTX.ST :
    * EGETIS SECURES CONDITIONAL ACCEPTANCE FOR EMCITATE® AS
BRAND
NAME IN THE US
    * CONDITIONAL ACCEPTANCE FROM US FOOD AND DRUG
ADMINISTRATION  FOR
USE OF BRAND NAME EMCITATE IN US
    * TO SUBMIT A NEW DRUG APPLICATION FOR EMCITATE FOR
TREATMENT OF
MONOCARBOXYLATE TRANSPORTER 8 DEFICIENCY MID-2023

Source text for Eikon:  ID:nMFN8ZcHYh 
Further company coverage:  EGTX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))